Jongsuksuntigul 1993.

Methods	Design: parallel group randomized trial Duration of study: 5–30 August 1991 Follow‐up: 14 days
Participants	Country: Thailand Kingdom Setting: community Number included in study: 196 Age: 3–80 years Sex: 98 male, 98 female Inclusion criteria: single or multiple infections of hookworm, Ascaris, and Trichuris Exclusion criteria: pregnant women and breastfeeding mothers Lost at follow‐up: 0 (0%) Number positive for A lumbricoides: 56 Number included in review: 56
Interventions	Treatment strategy: screening and treat all included participants Group 1: mebendazole 300 mg single dose (original) (n = 12) Group 2: mebendazole 300 mg single dose (n = 14) Group 3: mebendazole 500 mg single dose (n = 17) Group 4: albendazole 400 mg single dose (n = 13)
Outcomes	Outcomes included:Ascaris prevalence pre‐ and post‐treatment, cure rates, pre‐ and post‐treatment GM epg, ERR adverse events Outcomes not included in review: anthelmintic efficacy for hookworm, Trichuris, andEnterobius
Notes	Diagnostic technique: Kato‐Katz Funding support: SmithKline Beecham Pharmaceuticals Ltd and Janssen Pharmaceutica Ltd
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Details not reported. Quote: "patients were randomly assigned into four treatment groups."
Allocation concealment (selection bias)	Unclear risk	Details not reported.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Drugs had different appearance.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Quote: "The laboratory technicians were blind to the respective treatment of each patient group."
Incomplete outcome data (attrition bias) All outcomes	Low risk	All randomized participants included in analysis.
Selective reporting (reporting bias)	Low risk	All stated outcomes were reported.
Other bias	Unclear risk	Pharmaceutical support unclear.